Janette Sutton

Medicine · Health Sciences

13h-index1.2kcitations52works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(33), Monoclonal and Polyclonal Antibodies Research(21), Viral Infectious Diseases and Gene Expression in Insects(14), Lung Cancer Research Studies(8), Immunotherapy and Immune Responses(7)

Publications52 total

Figure FS4 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
2025Open Access
Supplementary Data 1 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
2025Open Access
Figure FS7 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
2025Open Access
Figure FS3 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
2025Open Access
Figure FS6 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
2025Open Access
Figure FS2 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
2025Open Access
Figure FS5 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
2025Open Access
Figure FS1 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
2025Open Access
280 Novel AND-gated LINK CAR-T cells demonstrate improved safety compared to 2nd-generation CAIX CAR-T cells for the treatment of clear cell renal cell carcinoma
Regular and Young Investigator Award Abstracts·2024Open Access
Constitutive Turbodomains enhance expansion and antitumor activity of allogeneic BCMA CAR T cells in preclinical models
Science Advances·2023· 17 citedOpen Access
Data from Design and Validation of Inducible TurboCARs with Tunable Induction and Combinatorial Cytokine Signaling
2023Open Access
Supplementary Data from Design and Validation of Inducible TurboCARs with Tunable Induction and Combinatorial Cytokine Signaling
2023Open Access
Supplementary Data from Design and Validation of Inducible TurboCARs with Tunable Induction and Combinatorial Cytokine Signaling
2023Open Access
Data from Design and Validation of Inducible TurboCARs with Tunable Induction and Combinatorial Cytokine Signaling
2023Open Access
Supplementary Data 1 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
2023Open Access
Data from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
2023Open Access
Figure FS6 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
2023Open Access
Figure FS7 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
2023Open Access
Supplementary Data 1 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
2023Open Access
Figure FS4 from Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Barbra J. Sasu(40), Thomas Van Blarcom(35), Siler H. Panowski(34), Zea Melton(32), Cecilia Lay(31), Yi Zhang(30), Tao Sai(26), Silvia K. Tacheva-Grigorova(25), Yvonne S.L. Mak(25), B. Smith(18), Javier Chaparro‐Riggers(14), Regina Lin(10), Cesar Sommer(8), Bijan Boldajipour(8), Arvind Rajpal(7), Bryan D. Smith(7), Pavel Strop(6), Julien Valton(6), Andrew R. Nager(6), Spencer Park(6)